LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
614 IndexMyelitis, and late radiation effect,
88, 93
Myeloablative conditioning
regimens, for allogeneic
transplantation, 525, 531
Myelodysplastic syndrome (MDS),
430, 438, 444, 459, 461
AML/RUNX1 in, 460, 461
cytogenetic abnormalities in, 459,
461
development of, 460, 461
HSCT in, 460, 461
IPSS for, 459–461
therapy-related, 460, 461
Myelogenous leukemias, 59, 65
Myelomonoblasts, 444
Myeloperoxidase and benzene, 58,
64
MYH-associated polyposis, 271,
276
Myotonic dystrophy, 224
Myxoid liposarcoma, 370
Nasopharyngeal cancer
EBV and, 52, 106, 111
symptoms of, 197
treatment, adjuvant
chemotherapy for, 201
types of, 197
The National Cancer Data Base
(NCDB), 587
National Cancer Institute (NCI),
587
National Cancer Institute of
Canada Clinical Trials Group,
250
National Comprehensive Cancer
Network (NCCN), 133, 274,
380, 587
National Health Interview Survey
(NHIS), 138
National Wilms Tumor Study
Group (NWTSG), 406–407
Natural killer (NK), 419, 432
cell vaccines, 107, 112
Nausea and vomiting, by opioid
analgesics, 563, 568
NBS1gene, 26
Necrolytic migratory erythema, 522
Necrosis, 20, 28
features of, 20, 28
Neoadjuvant chemotherapy, 282,
291, 365, 370
in breast cancer, 339, 347
in head and neck cancer, 96
in non-small cell lung cancer, 96
in pancreatic cancer, 96
Nephrotic syndrome, 224
NER.SeeNucleotide excision
repair (NER)Neuritic pain, management of, 575,
579
Neuroblastoma, 395, 404, 405
and autologous stem cell
transplantation, 530, 536
childhood, 397, 407–408
N-myc amplification in, 4, 11
Neurofibromatosis type 1 gene,
functions of, 395, 405
Neurofibromatosis type 1 (NF1),
35, 46, 365, 370
Neurofibromatosis type 2 (NF2),
linkage studies and, 388
Neuropathic pain, management of,
564, 570
Neutropenia, antibiotic prophylaxis
in, 539, 545
Neutropenic patients with
persistent fever, 547
liposomal amphotericin B for,
540, 546, 547
voriconazole for, 540, 546, 547
New England Journal of Medicine,
159
NF.SeeNuclear factor (NF)
NF1.SeeNeurofibromatosis Type 1
(NF1)
NF-kB.SeeNuclear factor-kappa B
(NF-kB)
NFB activation, 96, 97, 101, 102
NHEJ.SeeNonhomologous
end-joining (NHEJ)
NHIS.SeeNational Health
Interview Survey (NHIS)
NHL.SeeNon-Hodgkin’s
lymphoma (NHL)
Nicotine
and cancer formation, 43
measurement of, 135, 138
Nicotine replacement therapy
(NRT), 135, 138
smoking cessation and, 135,
138
2 4 nicotinic acetylcholine
receptor varenicline, 138
Nijmegen breakage syndrome 1,
26
Nijmegen disease, 18, 26
causes of, 18, 26
characteristics of, 26–27
Nitric oxide and CTC, 23, 31
NK.SeeNatural killer (NK)
NLPHL, transformation of, 422,
434
N-myc amplification, in
neuroblastoma, 4, 11
N-nitrosamines
esophageal cancer and, 43
lung cancer and, 43N-nitrosamines
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK),
44
N-nitrosonornicotine (NNN), 44
NNK.See N-nitrosamines
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone
(NNK)
NNN.See N-nitrosonornicotine
(NNN)
Nodular sclerosis (NS), 434
Non-Hodgkin’s lymphoma (NHL),
26, 49, 414
HIV-infection and, 50
Nonhomologous end-joining
(NHEJ), 85, 90
Nonirradiated cells, responses of,
86, 91
Nonmelanoma skin cancers, 53
Nonseminomatous germ cell tumor
(NSGCT), 215, 222, 298, 302
acute megakaryocytic leukemia
and, 220, 228
mediastinal, 227
retroperitoneal lymph node
dissection, 302
Non-small cell lung cancers
(NSCLC), 205, 210
adjuvant platinum-based
chemotherapy in, 207, 211
ALK testing in, 209, 213
carboplatin and, 206, 211
chemotherapy for, 206, 211
cisplatin in, 213
concurrent chemotherapy and
radiation, 208, 212
EML4–ALK translocations in,
210
erlotinib in, 207, 212
etoposide in, 213
oemetrexed maintenance therapy,
206, 211
paclitaxel in, 206, 211
Nonsmokers, defined, 135, 138
Nonsteroidal anti-inflammatory
drugs (NSAID), 36, 46, 136,
139
in colorectal cancer treatment,
136, 139
Nonvoluntary active euthanasia,
582, 586
Noonan’s syndrome, 413
Noxa, 19, 27
NPM1.SeeNucleophosmin 1
(NPM1)
NPM mutations, 443
NRT.SeeNicotine replacement
therapy (NRT)